{"id":"https://openalex.org/W4308386173","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.0703","title":"703 First-line tumor treating fields (TTFields; 150 kHz) therapy plus pembrolizumab for advanced or metastatic intrathoracic non-small cell lung cancer: the phase 2 EF-36/KEYNOTE B36 pilot study","display_name":"703 First-line tumor treating fields (TTFields; 150 kHz) therapy plus pembrolizumab for advanced or metastatic intrathoracic non-small cell lung cancer: the phase 2 EF-36/KEYNOTE B36 pilot study","publication_year":2022,"publication_date":"2022-11-01","ids":{"openalex":"https://openalex.org/W4308386173","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.0703"},"language":"en","primary_location":{"id":"doi:10.1136/jitc-2022-sitc2022.0703","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.0703","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-sitc2022.0703","pdf_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A736.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A736.full.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017206877","display_name":"Rupesh R Kotecha","orcid":"https://orcid.org/0000-0001-6927-0402","observed_orcids":["https://orcid.org/0000-0001-6927-0402"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rupesh Kotecha","raw_affiliation_strings":["Miami Cancer Institute, Miami, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Miami Cancer Institute, Miami, FL, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090256464","display_name":"Corey Jay Langer","orcid":"https://orcid.org/0000-0002-8483-6811","observed_orcids":["https://orcid.org/0000-0002-8483-6811"]},"institutions":[{"id":"https://openalex.org/I2799810409","display_name":"Hospital of the University of Pennsylvania","ror":"https://ror.org/02917wp91","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799810409","https://openalex.org/I4210143392"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Corey Langer","raw_affiliation_strings":["Hospital of University of Pensylvania, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital of University of Pensylvania, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I2799810409"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028226392","display_name":"Vinicius Ernani","orcid":"https://orcid.org/0000-0002-1865-5801","observed_orcids":["https://orcid.org/0000-0002-1865-5801"]},"institutions":[{"id":"https://openalex.org/I4210125099","display_name":"Mayo Clinic in Arizona","ror":"https://ror.org/03jp40720","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210125099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vinicius Ernani","raw_affiliation_strings":["Mayo Clinic Arizona, Phoenix, AZ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Mayo Clinic Arizona, Phoenix, AZ, USA","institution_ids":["https://openalex.org/I4210125099"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5057281549","display_name":"Anne S. Tsao","orcid":"https://orcid.org/0000-0003-0505-6639","observed_orcids":["https://orcid.org/0000-0003-0505-6639"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anne Tsao","raw_affiliation_strings":["MD Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MD Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":null,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"A736","last_page":"A736"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.42820000648498535,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.42820000648498535,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.3240000009536743,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":0.10409999638795853,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tumor-treating-fields","display_name":"tumor treating fields","score":0.984000027179718},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9470000267028809},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9739999771118164},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7620000243186951},{"id":"https://openalex.org/keywords/pd-l1-expression","display_name":"PD-L1 expression","score":0.843999981880188},{"id":"https://openalex.org/keywords/immunogenic-cell-death","display_name":"immunogenic cell death","score":0.8299999833106995},{"id":"https://openalex.org/keywords/pd-1-inhibitors","display_name":"PD-1 inhibitors","score":0.8190000057220459},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.6600000262260437},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.7770000100135803},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.5709999799728394},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7929999828338623},{"id":"https://openalex.org/keywords/immunotherapy-safety","display_name":"immunotherapy safety","score":0.36000001430511475},{"id":"https://openalex.org/keywords/immunotherapy-toxicity","display_name":"immunotherapy toxicity","score":0.3700000047683716},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.5490000247955322},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitor-related-pneumonitis","display_name":"immune-related pneumonitis","score":0.5400000214576721},{"id":"https://openalex.org/keywords/immune-mediated-colitis","display_name":"immune-related colitis","score":0.47200000286102295}],"concepts":[{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.8716806769371033},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8615557551383972},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6654120087623596},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6615304946899414},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6530348658561707},{"id":"https://openalex.org/C2777240266","wikidata":"https://www.wikidata.org/wiki/Q415220","display_name":"Pemetrexed","level":4,"score":0.6143268942832947},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.5934164524078369},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.515830934047699},{"id":"https://openalex.org/C117643217","wikidata":"https://www.wikidata.org/wiki/Q17824987","display_name":"Anaplastic lymphoma kinase","level":4,"score":0.4631464183330536},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.46076133847236633},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4532141089439392},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.44493404030799866},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2959650456905365},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.28760194778442383},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.2008388638496399},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1136/jitc-2022-sitc2022.0703","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.0703","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-sitc2022.0703","pdf_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A736.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"}],"best_oa_location":{"id":"doi:10.1136/jitc-2022-sitc2022.0703","doi":"https://doi.org/10.1136/jitc-2022-sitc2022.0703","is_oa":true,"landing_page_url":"https://doi.org/10.1136/jitc-2022-sitc2022.0703","pdf_url":"https://jitc.bmj.com/content/jitc/10/Suppl_2/A736.full.pdf","source":{"id":"https://openalex.org/S2754803477","display_name":"Journal for ImmunoTherapy of Cancer","issn_l":"2051-1426","issn":["2051-1426"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Regular and Young Investigator Award Abstracts","raw_type":"proceedings-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4308386173.pdf","grobid_xml":"https://content.openalex.org/works/W4308386173.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4389277087","https://openalex.org/W4294943486","https://openalex.org/W2612250812","https://openalex.org/W2740110736","https://openalex.org/W4399570450","https://openalex.org/W2569858041","https://openalex.org/W3105286732","https://openalex.org/W4389277049","https://openalex.org/W7120188876","https://openalex.org/W2898579896"],"abstract_inverted_index":{"Background":[0],"Tumor":[1],"Treating":[2],"Fields":[3],"(TTFields)":[4],"therapy":[5,23,42,114,197,337],"is":[6,56,93,99,226,236,309,353,382],"a":[7,37,90,100],"loco-regional":[8],"treatment":[9,119],"modality":[10],"approved":[11,126,408],"for":[12,117,135,373,417],"glioblastoma":[13],"and":[14,79,108,151,256,260,268,281,285,289,293,301,318,334,344],"malignant":[15],"pleural":[16],"mesothelioma.":[17],"Effectiveness":[18],"of":[19,45,82,86,110,120,251,351,362,391],"TTFields":[20,41,74,111,196,336],"(150":[21,112],"kHz)":[22,113],"plus":[24,43,115],"pemetrexed":[25],"in":[26,36,60,89,221,262],"recurrent":[27],"non-small":[28],"cell":[29,77],"lung":[30],"cancer":[31],"(NSCLC)":[32],"was":[33,125,407],"previously":[34],"demonstrated":[35],"phase":[38,63,102],"1/2":[39],"study.":[40],"standard":[44],"care":[46],"(SOC;":[47],"docetaxel":[48],"or":[49,154,175],"immune":[50],"checkpoint":[51],"inhibitors)":[52],"vs":[53,191],"SOC":[54],"alone":[55],"currently":[57],"being":[58],"evaluated":[59],"the":[61,128,202,307,331,410],"large":[62],"3":[64,211],"LUNAR":[65],"study":[66,105,124,406],"(NCT02973789).":[67],"Given":[68],"that":[69,73],"preclinical":[70],"data":[71],"show":[72],"induce":[75],"immunogenic":[76],"death":[78],"enhance":[80],"efficacy":[81,107],"PD-1":[83],"inhibitors,":[84],"investigation":[85],"this":[87],"combination":[88],"clinical":[91],"population":[92],"warranted.":[94],"Methods":[95],"EF-36/KEYNOTE":[96],"B36":[97],"(NCT04892472)":[98],"multicenter,":[101],"2,":[103],"open-label":[104],"evaluating":[106],"safety":[109],"pembrolizumab":[116,206],"first-line":[118],"advanced":[121,153],"NSCLC.":[122],"The":[123,275,405],"by":[127,185,409],"institutional":[129,411],"review":[130,412],"board/ethics":[131,413],"committee":[132,414],"as":[133,415],"required":[134,354,416],"each":[136,418],"participating":[137,419],"site.":[138],"Patients":[139,168,183],"(\u2265":[140],"22":[141],"years)":[142],"with":[143,169,205,228,264,283,316,394],"Eastern":[144],"Cooperative":[145],"Oncology":[146],"Group":[147],"performance":[148],"status":[149],"0\u20131":[150],"treatment-na\u00efve":[152],"metastatic":[155],"intrathoracic,":[156],"PD-L1":[157,186],"positive":[158],"(tumor":[159],"proportion":[160],"score":[161],"[TPS]":[162],"\u2265":[163,189,198,266,395],"1%)":[164],"NSCLC":[165,180],"are":[166,181,271],"eligible.":[167],"epidermal":[170],"growth":[171],"factor":[172],"receptor-sensitizing":[173],"mutations":[174],"anaplastic":[176],"lymphoma":[177],"kinase":[178],"translocation":[179],"ineligible.":[182],"stratified":[184],"expression":[187],"(TPS":[188],"50%":[190,267],"TPS":[192,265,269],"1\u201349%)":[193],"will":[194,278,387],"receive":[195],"18":[199],"h/day,":[200],"via":[201,297],"NovoTTF-200T":[203,332],"System,":[204],"200":[207],"mg":[208],"intravenously":[209],"every":[210],"weeks":[212],"(Q3W),":[213],"until":[214],"disease":[215,253],"progression":[216],"per":[217],"Response":[218],"Evaluation":[219],"Criteria":[220],"Solid":[222],"Tumors":[223],"v1.1.":[224],"Follow-up":[225],"Q3W,":[227],"computerized":[229],"tomography":[230],"(CT)":[231],"scans":[232],"Q9W.":[233],"Primary":[234],"endpoint":[235],"objective":[237],"response":[238],"rate":[239],"(ORR).":[240],"Secondary":[241],"endpoints":[242],"include":[243],"overall":[244],"survival":[245,248],"(OS),":[246],"progression-free":[247],"(PFS),":[249],"duration":[250,343],"response,":[252],"control":[254],"rate,":[255],"safety.":[257],"ORR,":[258],"OS,":[259],"PFS":[261],"patients":[263,280,317,327,393],"1\u201349%":[270],"also":[272],"secondary":[273],"endpoints.":[274],"device":[276,308],"manufacturer":[277],"provide":[279],"caregivers":[282],"technical":[284],"lifestyle":[286],"integration":[287],"training,":[288],"guidance":[290],"on":[291],"preventing":[292],"managing":[294],"skin":[295],"effects,":[296],"Device":[298],"Support":[299],"Specialists":[300],"field":[302],"personnel.":[303],"Usage":[304],"information":[305],"from":[306],"provided":[310],"to":[311,313,355,359,379],"physicians":[312],"aid":[314],"discussions":[315],"maximize":[319],"usage.":[320],"This":[321],"novel":[322],"support":[323],"framework":[324],"helps":[325],"ensure":[326],"can":[328],"confidently":[329],"operate":[330],"System":[333],"integrate":[335],"into":[338],"daily":[339],"life,":[340],"improving":[341],"usage":[342],"optimizing":[345],"patient":[346],"outcomes.":[347],"A":[348],"sample":[349],"size":[350],"66":[352],"achieve":[356],"80%":[357],"power":[358],"detect":[360],"ORR":[361],"40%":[363],"at":[364],"1-sided":[365],"alpha":[366],"level":[367],"0.1,":[368],"using":[369],"1-sample":[370],"exact":[371],"test":[372],"proportion,":[374],"considering":[375],"<":[376],"10%":[377],"loss":[378],"follow-up.":[380],"Recruitment":[381],"ongoing;":[383],"planned":[384],"interim":[385],"analysis":[386],"occur":[388],"after":[389],"enrollment":[390],"15":[392],"1":[396],"follow-up":[397],"CT":[398],"scan.":[399],"Trial":[400],"Registration":[401],"NCT04892472":[402],"Ethics":[403],"Approval":[404],"site":[420]},"counts_by_year":[{"year":2023,"cited_by_count":1}],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2022-11-11T00:00:00"}